Abstract 330P
Background
The global Covid Pandemic has changed the world in last 6 months. The medical, social and logistic effects of the pandemic have been enormous. Many countries including India were put in absolute lockdown to prevent the transmission of this deadly virus. Cancer patients were precariously placed with the effect of lockdown as their immunocompromised status predisposed them to complications due to Covid while if they follow the lockdown, they were at increased risk of disease progression. This is an retrospective study from a tertiary Cancer Institute in Delhi, India which analyses the outcomes of COVID positivity in cancer patients undergoing treatment.
Methods
35 patients undergoing treatment for various non hematological malignancies and who were detected Covid positive by RT PCR were analysed. The time period was between April 2020 and June 2020.
Results
35 patients were analysed. 10 patients had NSCLC while 7 patients had ca breast.Remaining all patients had various non hematological malignancies. Out of which 22 patients were managed on OPD basis and 13 patients required hospitalisation. Out of 13 patients, 3 patients required ICU care in view of severe symptoms. 2 patients died of the disease and superimposed Covid infections. Out of these, 1 patient had received chemo in the prior week whilst the other had progressive disease and GI perforation as the cause of the mortality. Chemotherapy was restarted in 15 of these patients while 2 patients also underwent surgery after recovery.
Conclusions
In our dataset, Covid infection was not associated with increased risk of mortality and morbidity in Cancer patients. Large scale collective data sets are required to confirm these findings. Our data indicates that Oncological treatment should continue as usual in Covid pandemic while taking appropriate precautions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session